US Pharma MarketingZymeworks CEO on why the Theravance deal is value for money
Zymeworks CEO Kenneth Galbraith makes the case for the $929M Theravance deal, arguing the net outlay is only about $120M. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
Source: Endpoints News